(ENXTBR:ARGX) reported positive topline data from its Phase 3 ADAPT OCULUS trial of VYVGART in ocular myasthenia gravis. The study met its primary endpoint, with statistically significant improvement ...

Efgartigimod alfa–hyaluronidase significantly improves ocular symptoms in adults with ocular myasthenia gravis, according to phase 3 trial data.

Three drugs that inhibit the immunoglobulin G (IgG) neonatal fragment crystallizable receptor (FcRn) were approved to treat generalized myasthenia gravis (MG) in recent years: efgartigimod (Vyvgart), ...

Alexion, AstraZeneca Rare Disease's Ultomiris® (ravulizumab rch) has been listed on the Pharmaceutical Benefits Scheme (PBS) for adults with ...

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG ...

Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS) ...

X recently announced results from additional analyses of its blockbuster FcRn inhibitor Vyvgart in the phase III Adapt Oculus study. The study evaluated the efficacy and safety of Vyvgart administered ...

NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravisAarhus, ...

The Adapt Oculus trial is unique in that it includes a patient population often overlooked in clinical trials, patients ...

Argenx Se ( (ARGX)) has provided an update. On March 6, 2026, Argenx announced it will present extensive new data on VYVGART and its neurology pipeline at the American Academy of Neurology Annual ...

Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A ...